Saltar ao contenido
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Idioma
Todos os campos
Title
Autor
Subject
Número de Clasificación
ISBN/ISSN
Tag
Buscar
Avanzado
Lack of minority K65R-resistan...
Citar
Text this
Enviar este rexistro por email
Imprimir
Exportar rexistro
Exportar a RefWorks
Exportar a EndNoteWeb
Exportar a EndNote
Permanent link
Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.
Detalles Bibliográficos
Main Authors:
McCormick, A
,
Goodall, R
,
Joyce, A
,
Ndembi, N
,
Chirara, M
,
Katundu, P
,
Walker, S
,
Yirrell, D
,
Gilks, C
,
Pillay, D
Formato:
Journal article
Idioma:
English
Publicado:
2010
Existencias
Descripción
Títulos similares
Staff View
Títulos similares
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
por: Ndembi, N, et al.
Publicado: (2010)
Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
por: Green, H, et al.
Publicado: (2007)
Brain antioxidants and hippocampal microanatomical alterations following the administration of Efavirenz/Lamivudine/Tenofovir disoproxil fumarate and Lamivudine/Nevirapine/Zidovudine in adult male Wistar rats
por: Innocent A. Edagha, et al.
Publicado: (2022-06-01)
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
por: Gibb, D, et al.
Publicado: (2002)
Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus.
por: Yu Cong, et al.
Publicado: (2016-01-01)